Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01706458 · ClinicalTrials.gov registry record · Phase 2
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT01706458 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 18 participants.
The verdict
NCT01706458, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies sipuleucel-T with or without deoxyribonucleic acid (DNA) vaccine therapy in treating patients with prostate cancer that has not responded to previous treatment with hormones and has spread to other places in the body. Vaccines may help the body build an effective immune response to kill tumor cells. It is not yet known whether giving sipuleucel-T vaccine works better with or without DNA vaccine therapy in treating prostate cancer.
Interventions
- BIOLOGICAL DNA Vaccine
- BIOLOGICAL sipuleucel-T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2013-05-20 |
| Est. Completion | 2020-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01706458
The ClinicalTrials.gov registry entry for NCT01706458 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which DNA Vaccine is the first listed.
NCT01706458 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01706458 about?
NCT01706458 is a clinical study titled "Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer". This randomized pilot clinical trial studies sipuleucel-T with or without deoxyribonucleic acid (DNA) vaccine therapy in treating patients with prostate cancer that has not responded to previous treatment with hormones and has spread to other places in the body. Vaccines may help the body build an e...
What is the current status of trial NCT01706458?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2013-05-20. Estimated completion is 2020-08-13.
What interventions are being tested in trial NCT01706458?
The interventions under investigation include: DNA Vaccine (BIOLOGICAL), sipuleucel-T (BIOLOGICAL).
Who is sponsoring clinical trial NCT01706458?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.